Diagnosis and treatment of progressive multiple sclerosis: A position paper.
Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, Airas L, Oreja-Guevara C.
Eur J Neurol. 2023 Jan;30(1):9-21. doi: 10.1111/ene.15593. Epub 2022 Oct 25.
Secondary Progressive Multiple Sclerosis: New Insights.
Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H.
Neurology. 2021 Aug 24;97(8):378-388. doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4.
Progressive multiple sclerosis: pathology and pathogenesis.
Lassmann H, van Horssen J, Mahad D.
Nat Rev Neurol. 2012 Nov 5;8(11):647-56. doi: 10.1038/nrneurol.2012.168. Epub 2012 Sep 25.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE.
EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22.
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.
Yong HYF, Yong VW.
Nat Rev Neurol. 2022 Jan;18(1):40-55. doi: 10.1038/s41582-021-00581-x. Epub 2021 Nov 3.
Progressive Multiple Sclerosis.
Ontaneda D.
Continuum (Minneap Minn). 2019 Jun;25(3):736-752. doi: 10.1212/CON.0000000000000727.
Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA.
Carlson AK, Fox RJ.
Neurol Clin. 2024 Feb;42(1):39-54. doi: 10.1016/j.ncl.2023.07.002. Epub 2023 Aug 21.
Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
Rodriguez de Antonio LA, Cuberta-Gonzalez I, Garcia-Castañon I, Oreja-Guevara C.
Mult Scler Relat Disord. 2023 Jan;69:104441. doi: 10.1016/j.msard.2022.104441. Epub 2022 Dec 5.
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review.
Pietrasik S, Dziedzic A, Miller E, Starosta M, Saluk-Bijak J.
Int J Mol Sci. 2021 Nov 2;22(21):11887. doi: 10.3390/ijms222111887.
The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D.
J Autoimmun. 2014 Feb-Mar;48-49:134-42. doi: 10.1016/j.jaut.2014.01.022. Epub 2014 Feb 10.
